Researchers home in on headache-causing compounds in red wine
It’s not the tannins or sulfites after all.
Related Articles
Health Impacts of Micro- and Nanoplastics
In preparation for a proposed international treaty on plastic pollution, leading experts discussed the health dangers involved.
Seven consortia selected to establish AI factories which will boost AI innovation in the EU
The European High Performance Computing Joint Undertaking (EuroHPC) has selected seven proposals to establish and operate the first AI Factories across Europe.
Stop spam calls, texts, and voicemail!
YouMail delivers a free spam call blocking app with premium professional call handling. Exploring the forefront of telecommunications security with YouMail….
Redefining Brilliance in the Context of Human Virtue
Personal Perspective: Perhaps virtue is the true genius of our time—a guiding force that ensures brilliance to serve humanity, not the other way around.
Gaza: UK doctors recount horrific hospital scenes as they urge Keir Starmer to act
UK doctors who have returned from Gaza have described the situation as “absolutely dire,” recalling blood soaked beds, emaciated colleagues and patients, and doctors forced…
Drone detection system deployed to New York after mystery sightings
The state governor has asked for more federal support as questions grow over objects spotted in the skies.
Zocdoc CEO Predicts 3 Ways the Healthcare Industry Will Change in 2025 – MedCity News
Zocdoc CEO Oliver Kharraz has some predictions about how healthcare will change in 2025 — including the rise of cash-pay services and the potential restructuring…
Making CAR T-cell therapies more affordable
CAR T-cell therapies have revolutionised treatment of many diseases, but their expense means many patients are unable to benefit. Kathryn Senior reports.
Register for Modern Healthcare’s 2030 Playbook Conference
At The 2030 Playbook Conference – Strategies and Solutions for the Future of Healthcare, leaders will address how they plan to hit their five-year goals.
Merck discontinues development of 2 experimental cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
